BioNTech Q1 2026: €118M Revenue, $1B Buyback, Five New Pivotal Oncology Trials Initiated

On May 4, 2026, BioNTech released Q1 2026 financial results showing revenue of €118.1M (vs. €182.8M in Q1 2025, a 35% YoY decline reflecting continued post-COVID normalization). GAAP net loss was €531.9M, with R&D expenses growing to €557.0M driven by intensive oncology and ADC pipeline investment. Despite the revenue decline, BioNTech reported a cash position of €19.6B as of March 31, 2026, providing substantial runway. The company announced a $1.0 billion share repurchase program over 12 months, signaling financial confidence. Key pipeline milestones: BioNTech initiated five new pivotal trials for pumitamig across triple-negative breast cancer, MSS colorectal cancer, gastric cancer, and two NSCLC settings, with interim Phase 3 data readouts expected in H2 2026. BNT111 (shared-antigen mRNA melanoma vaccine) remains in Phase 3 with results expected by year-end 2026. BNT116 (NSCLC mRNA vaccine targeting six tumor-associated antigens) showed 45% objective response rate and 80% disease control rate in Phase 1 combination data with cemiplimab presented earlier in 2026. BioNTech also announced manufacturing restructuring: planned exit of sites in Idar-Oberstein, Marburg, and Tübingen (by end 2027) and Singapore (Q1 2027), targeting ~€500M in annual cost savings by 2029.